Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
about
Medical treatment of early stage and rare histological variants of epithelial ovarian cancerThe prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.SOX2 is required to maintain cancer stem cells in ovarian cancer.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.GPR30 predicts poor survival for ovarian cancerOvarian cancer development and metastasis.BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histologyDiagnosis, treatment, and follow-up of borderline ovarian tumorsMolecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.Fallopian tube origin of supposed ovarian high-grade serous carcinomas.Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinomaSurvival in women with grade 1 serous ovarian carcinomaOvarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problemsThe transcriptomic profile of ovarian cancer gradingIntratumoral heterogeneity in a minority of ovarian low-grade serous carcinomasThe insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.Microenvironment and pathogenesis of epithelial ovarian cancerBevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancerHormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.Ovarian cancer: opportunity for targeted therapy.Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancerLow-grade serous carcinomas of the ovary contain very few point mutationsRecent progress in the diagnosis and treatment of ovarian cancerImpact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancerEvaluating cell lines as tumour models by comparison of genomic profiles.Genetic and molecular changes in ovarian cancer.Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma.Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.Critical molecular abnormalities in high-grade serous carcinoma of the ovary.Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.
P2860
Q26777702-25FB3420-F593-4681-9E98-959C552B6E7CQ30405874-0EC444BA-E06D-477B-B1DD-9B9A7DA01C86Q30410498-12EEC21D-10C7-48C7-BC80-0276B3C469A9Q33580777-1AB028B8-6528-4622-B72D-D2499EADA458Q33598001-73116715-94C4-43EA-9809-CF1CBE716EEFQ33607622-C24729A1-0B6F-40FA-B2C9-E93E1D3CD25FQ33735170-963B9791-29BD-470A-B56B-95AF39E5DB01Q34066297-97191C35-A79D-499F-9958-D2A6828FA3EAQ34086819-0AD4DC55-0C70-442E-AE5F-EF76C9117D01Q34162272-E9C3A347-9BA2-4A06-AA39-6654B0E47860Q34387999-5A8FB26B-DB19-4FB0-B9DD-80F3D9206226Q34424902-B210E868-0491-4CDD-AD21-369A1BED656CQ34565756-218142FE-67E4-42F2-BC5E-16098141BCB0Q34604042-3977F351-3C56-409D-B868-227589D7F567Q34626854-5626577D-342C-4FB4-9D39-4E146EEB2461Q34967339-57251839-1193-4EF2-A2E2-D96E297A36B2Q34998994-87962F18-8EEF-47BC-9A2A-13027E361250Q35032309-0F0850E8-EBA4-409A-8FAD-849D754B214AQ35060446-B27C15FA-4B10-43A0-B3FC-93A097DA4B34Q35209365-11E81FF8-1613-43B6-88B4-2FD9E9D41337Q35419057-BDC0AC5D-9F62-4BD8-B188-9DB158A8F2F0Q35461505-1F1DA666-DB2A-4C8B-8A29-65478107C345Q35510378-69E83F2A-F500-4CB2-AA59-A02EC57EBAEFQ35659945-9C20D5BE-2EAA-41C3-B3F8-75D42CB2AC5EQ35947034-47F55E63-FA97-4605-8CE9-D234671C3CCBQ35980522-0256593F-A03C-4E48-9AE5-F279A41EE10AQ35983825-CDC10848-901C-4C7C-8816-F40016C95AF0Q36415602-A83AA666-A77F-42F9-A43E-B220FA8F814BQ36622857-BC835197-800F-4D71-97B5-D1968B611E6CQ36750622-2BBD5BA1-67F0-44D9-9D33-FC617AE81E26Q36751103-0B06BA3D-7187-477B-86F4-2043A56C60C3Q36768921-C870ED70-8A55-49E9-A5CC-0FB7D01B7FA6Q36855239-7AF189A3-56B3-4C7C-A50E-E1ADC031FC5FQ37025950-E490C15A-C41A-40E2-9BE3-69AC1A745F57Q37094076-9DD3FDD4-C832-413B-AF15-E608D9C94E92Q37101060-F312A428-2E9E-4912-B4D5-4549BD61811CQ37104731-EB84E83D-F0DB-4EB8-AD2D-5D7E3B0D2061Q37183300-7A8EAF17-7FF5-4C39-8EEE-387CC8E82F0DQ37232123-57E8B03E-A250-4BEB-B0F3-645F262ED8C6Q37276915-57844833-32D3-4650-A245-2651A2653406
P2860
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
@en
type
label
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
@en
prefLabel
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
@en
P2093
P1476
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
@en
P2093
Anil K Sood
Charlotte C Sun
David M Gershenson
Diane C Bodurka
Elvio G Silva
Karen H Lu
Michael T Deavers
Robert L Coleman
P304
P356
10.1097/01.AOG.0000227787.24587.D1
P407
P577
2006-08-01T00:00:00Z